Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) CFO David Parrot bought 2,666 shares of the stock in a transaction dated Thursday, July 23rd. The stock was bought at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the acquisition, the chief financial officer directly owned 1,333 shares of the company’s stock, valued at approximately $19,995. This represents a -200.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Scribe Therapeutics Stock Down 4.8%
Shares of NASDAQ:SCTX opened at $18.06 on Wednesday. Scribe Therapeutics Inc. has a fifty-two week low of $17.31 and a fifty-two week high of $25.49.
Featured Articles
- Five stocks we like better than Scribe Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
